313 related articles for article (PubMed ID: 15306255)
1. Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia.
Matucz E; Móricz K; Gigler G; Simó A; Barkóczy J; Lévay G; Hársing LG; Szénási G
Brain Res; 2004 Sep; 1019(1-2):210-6. PubMed ID: 15306255
[TBL] [Abstract][Full Text] [Related]
2. A dose-response study of neuroprotection using the AMPA antagonist NBQX in rat focal cerebral ischemia.
Graham SH; Chen J; Lan JQ; Simon RP
J Pharmacol Exp Ther; 1996 Jan; 276(1):1-4. PubMed ID: 8558416
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic time window of neuroprotection by non-competitive AMPA antagonists in transient and permanent focal cerebral ischemia in rats.
Matucz E; Móricz K; Gigler G; Benedek A; Barkóczy J; Lévay G; Hársing LG; Szénási G
Brain Res; 2006 Dec; 1123(1):60-7. PubMed ID: 17064671
[TBL] [Abstract][Full Text] [Related]
4. High-dose methylprednisolone treatment in experimental focal cerebral ischemia.
Slivka AP; Murphy EJ
Exp Neurol; 2001 Jan; 167(1):166-72. PubMed ID: 11161604
[TBL] [Abstract][Full Text] [Related]
5. Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats.
Campbell CA; Mackay KB; Patel S; King PD; Stretton JL; Hadingham SJ; Hamilton TC
Exp Neurol; 1997 Nov; 148(1):45-50. PubMed ID: 9398449
[TBL] [Abstract][Full Text] [Related]
6. Post-treatment of transient focal cerebral ischemia in rats with the novel cerebrovascular-selective Ca2+ channel antagonist (+/-)-(E)-1-(3-fluoro-6,11-dihydrodibenz[b,e]-oxepine-11-yl)-4-(3-pheny l-2-propenyl)-piperazine dimaleate.
Minato H; Kikuta C; Masuda Y; Fujitani B; Hosoki K
Arzneimittelforschung; 1997 Jul; 47(7):799-802. PubMed ID: 9272234
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of a postischemic treatment with a bradykinin B2 receptor antagonist in a rat model of temporary focal cerebral ischemia.
Lumenta DB; Plesnila N; Kläsner B; Baethmann A; Pruneau D; Schmid-Elsaesser R; Zausinger S
Brain Res; 2006 Jan; 1069(1):227-34. PubMed ID: 16378603
[TBL] [Abstract][Full Text] [Related]
8. The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia.
Gill R
Cerebrovasc Brain Metab Rev; 1994; 6(3):225-56. PubMed ID: 7529037
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective effect of NMDA receptor glycine recognition site antagonism persists when brain temperature is controlled.
Takaoka S; Bart RD; Pearlstein R; Brinkhous A; Warner DS
J Cereb Blood Flow Metab; 1997 Feb; 17(2):161-7. PubMed ID: 9040495
[TBL] [Abstract][Full Text] [Related]
10. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of focal cerebral ischemia.
Gotti B; Duverger D; Bertin J; Carter C; Dupont R; Frost J; Gaudilliere B; MacKenzie ET; Rousseau J; Scatton B
J Pharmacol Exp Ther; 1988 Dec; 247(3):1211-21. PubMed ID: 2849668
[TBL] [Abstract][Full Text] [Related]
11. A selective endothelin ET(A) receptor antagonist, SB 234551, improves cerebral perfusion following permanent focal cerebral ischemia in rats.
Zhang Y; Belayev L; Zhao W; Irving EA; Busto R; Ginsberg MD
Brain Res; 2005 May; 1045(1-2):150-6. PubMed ID: 15910773
[TBL] [Abstract][Full Text] [Related]
12. Magnesium sulfate fails to reduce infarct volume following transient focal cerebral ischemia in rats.
Zhu HD; Martin R; Meloni B; Oltvolgyi C; Moore S; Majda B; Knuckey N
Neurosci Res; 2004 Jul; 49(3):347-53. PubMed ID: 15196783
[TBL] [Abstract][Full Text] [Related]
13. Extended therapeutic time window after focal cerebral ischemia by non-competitive inhibition of AMPA receptors.
Elger B; Gieseler M; Schmuecker O; Schumann I; Seltz A; Huth A
Brain Res; 2006 Apr; 1085(1):189-94. PubMed ID: 16580649
[TBL] [Abstract][Full Text] [Related]
14. Infarct reduction in rats following intraventricular administration of either tissue plasminogen activator (tPA) or its non-protease mutant S478A-tPA.
Yi JS; Kim YH; Koh JY
Exp Neurol; 2004 Oct; 189(2):354-60. PubMed ID: 15380485
[TBL] [Abstract][Full Text] [Related]
15. Neuroprotective effects of the CRF1 antagonist R121920 after permanent focal ischemia in the rat.
Mackay KB; Bozigian H; Grigoriadis DE; Loddick SA; Verge G; Foster AC
J Cereb Blood Flow Metab; 2001 Oct; 21(10):1208-14. PubMed ID: 11598498
[TBL] [Abstract][Full Text] [Related]
16. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat.
Bordi F; Pietra C; Ziviani L; Reggiani A
Exp Neurol; 1997 Jun; 145(2 Pt 1):425-33. PubMed ID: 9217078
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotection (focal ischemia) and neurotoxicity (electroencephalographic) studies in rats with AHN649, a 3-amino analog of dextromethorphan and low-affinity N-methyl-D-aspartate antagonist.
Tortella FC; Britton P; Williams A; Lu XC; Newman AH
J Pharmacol Exp Ther; 1999 Oct; 291(1):399-408. PubMed ID: 10490930
[TBL] [Abstract][Full Text] [Related]
18. Post-treatment with selective β1 adrenoceptor antagonists provides neuroprotection against transient focal ischemia in rats.
Goyagi T; Horiguchi T; Nishikawa T; Tobe Y
Brain Res; 2010 Jul; 1343():213-7. PubMed ID: 20451506
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effect of tacrolimus (FK506) on ischemic brain damage following permanent focal cerebral ischemia in the rat.
Noto T; Ishiye M; Furuich Y; Keida Y; Katsuta K; Moriguchi A; Matsuoka N; Aramori I; Goto T; Yanagihara T
Brain Res Mol Brain Res; 2004 Sep; 128(1):30-8. PubMed ID: 15337315
[TBL] [Abstract][Full Text] [Related]
20. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport.
Hurtado O; Moro MA; Cárdenas A; Sánchez V; Fernández-Tomé P; Leza JC; Lorenzo P; Secades JJ; Lozano R; Dávalos A; Castillo J; Lizasoain I
Neurobiol Dis; 2005 Mar; 18(2):336-45. PubMed ID: 15686962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
